Need more? Try out  Advanced Search (20+ criteria)»

Last Update

is this you? Claim your profile.

Wrong Gilad Rosenberg?

Gilad Rosenberg

Vice President, Clinical Development

D-Pharm Ltd

HQ Phone:  +972 8-938-5100

Direct Phone: +972 *-***-**** ext. ***direct phone

GET ZOOMINFO GROW

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions.

I agree to the  Terms of Service and  Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

THANK YOU FOR DOWNLOADING!

computers
  • 1.Download
    ZoomInfo Grow
    v sign
  • 2.Run Installation
    Wizard
  • 3.Check your inbox to
    Sign in to ZoomInfo Grow

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Community Edition at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

D-Pharm Ltd

Kiryat Weizmann Science Park Bldg 7

Rehovot, Central District,76123

Israel

Company Description

D-Pharm (http://www.dpharm.com) is a clinical stage, technology-driven biopharmaceutical company developing proprietary products for treatment of CNS disorders. D-Pharm's pipeline includes three clinical stage (phase 2) products, i.e., THR-18 for thrombolysis,... more.

Find other employees at this company (34)

Web References(21 Total References)


D-Pharm Raises 12.8 M NIS | BioIsrael – Israel's Life Sciences On-Line

www.bioisrael.com [cached]

Similarly, THR-18 reduced by more than twice the occurrence of brain edema (p Dr. Gilad Rosenberg, D-Pharm's VP of Clinical Development commented, "It is certainly encouraging to see the reduced rates of brain swelling and intracranial bleeding in the tPA-treated stroke patients given THR-18, and I look forward to see whether these findings translate into less disability and better neurological recovery once the clinical endpoint data become available for the full data set."


www.prnewswire.com

Dr. Gilad Rosenberg, D-Pharm's VP of Clinical Development, commented: "There is currently no effective specific treatment for acute pancreatitis, and patients only receive symptomatic therapy.


www.biospace.com

D-Pharm's VP for Clinical Development, Dr. Gilad Rosenberg, commented: "We are excited to continue the clinical testing of THR-18.


bionews.zampbioworld.org

Dr. Gilad Rosenberg, D-Pharm's VP Clinical Development commented: "I'm delighted that we've achieved this important milestone.


Academic Journals Inc.

www.academicjournals.com [cached]

Dr. Gilad Rosenberg, D-Pharm's V.P. Clinical Development stated, "We're very pleased that this important clinical milestone has been achieved on schedule.


Similar Profiles

city

Browse ZoomInfo's Business
Contact Directory by City

city

Browse ZoomInfo's
Business People Directory

city

Browse ZoomInfo's
Advanced Company Directory